Leucofeligen FeLV/RCP

RSS

feline calicivirosis, feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live), feline leukaemia vaccine (inactivated)

Authorised
This medicine is authorised for use in the European Union.

Overview

Leucofeligen FeLV/RCP is a vaccine used to protect cats from eight weeks of age against the following diseases:

  • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus);
  • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus);
  • feline panleucopenia (a serious illness causing bloody diarrhoea and a fall in white blood cell counts caused by a parvovirus);
  • feline leukaemia (an illness affecting the immune system causing loss of appetite, weight loss, poor fur condition, fever, pale gums and diarrhoea caused by a retrovirus).

The vaccine helps to reduce the signs of these diseases. It also prevents feline panleucopenia and persistent viraemia for feline leukaemia (the presence of feline leukaemia virus in the blood).

The vaccine contains live feline viruses that have been attenuated (weakened) so they do not cause disease: feline calicivirus (strain F9), viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72). It also contains a protein of feline leukaemia virus (FeLV).

This EPAR was last updated on 13/06/2019

Authorisation details

Product details
Name
Leucofeligen FeLV/RCP
Agency product number
EMEA/V/C/000143
Active substance
  • live feline calicivirus (strain F9) / live feline viral rhinotracheitis virus (strain F2) / live feline panleucopenia virus
  • purified p45 feline leukaemia virus envelope antigen
International non-proprietary name (INN) or common name
feline calicivirosis, feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live), feline leukaemia vaccine (inactivated)
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI06AH07
Publication details
Marketing-authorisation holder
Virbac S.A.
Revision
7
Date of issue of marketing authorisation valid throughout the European Union
24/06/2009
Contact address

1ère Avenue 2065 M - L.I.D.
06516 Carros Cedex
France

Product information

17/04/2019 Leucofeligen FeLV/RCP - EMEA/V/C/000143 - WS/1483

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

live feline panleucopenia virus / parvovirus + live feline rhinotracheitis virus + live feline calicivirus + inactivated feline leukaemia virus

Therapeutic indication

For active immunisation of cats from eight weeks of age against:

  • feline calicivirosis to reduce clinical signs.
  • feline viral rhinotracheitis to reduce clinical signs and viral excretion.
  • feline panleucopenia to prevent leucopenia and to reduce clinical signs.
  • feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.
  • Onset of immunity: 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, and 4 weeks after the primary vaccination for the calicivirus and rhinotracheitis virus components.
  • Duration of immunity: one year after the primary vaccination for all components.

Assessment history

How useful was this page?

Add your rating
Average
1 rating